Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures

European Journal of Clinical Pharmacology
Anna DmoszynskaNorbert Grzasko

Abstract

Multiple myeloma is characterized by an accumulation of plasma cells in bone marrow. Despite many therapeutic regimens introduced recently, the prognosis for patients suffering from treatment-resistant or relapsing multiple myeloma is still very poor. Thus, there is an urgent medical need for novel innovative drugs. Thalidomide is successfully used in resistant or relapsing myeloma patients, being reported to induce apoptosis or G1 growth arrest of myeloma cells and to regulate microvessel density and cytokine secretion. Lovastatin, largely used for the treatment of hypercholesterolemia, is another promising drug in multiple myeloma. High doses of lovastatin have been shown to have antiproliferative effect by inhibition of malignant cell proliferation and inducing programmed cell death. In this study, we tried to assess whether thalidomide and lovastatin had a combined effect on apoptosis of myeloma cells. We analyzed apoptosis induced by mixture of these two drugs in short-term cell culture of myeloma plasmocytes. To assess apoptosis, we used Annexin V and propidium iodide binding. We also examined the regulation of BCL-2 and BAX protein expression in the population of CD138+ plasmocytes. The cells were analyzed with the use o...Continue Reading

References

Mar 1, 1991·The Journal of Experimental Medicine·E P SampaioG Kaplan
May 1, 1995·Cellular Immunology·A LichtensteinJ Berenson
Jan 23, 1999·Oncogene·J C Reed
Nov 24, 1999·Immunology Today·J B MarriottA G Dalgleish
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Feb 26, 2000·British Journal of Haematology·A KnellerI Ben-Bassat
Apr 27, 2000·The American Journal of Medicine·L Calabrese, A B Fleischer
Aug 2, 2001·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·M LishnerI Fabian
Feb 13, 2002·Circulation·Michael WeisJohn P Cooke
Apr 22, 2004·The Journal of Pharmacy and Pharmacology·Yahya MrestaniReinhard H H Neubert

❮ Previous
Next ❯

Citations

Jan 9, 2008·Cancer Letters·Antonella Sassano, Leonidas C Platanias
Jun 16, 2009·Medicinal Research Reviews·Marek Jakobisiak, Jakub Golab
Feb 26, 2013·Leukemia Research·Adrianna Slawinska-BrychMartyna Kandefer-Szerszen
Mar 19, 2014·Anti-cancer Drugs·Tao YangXiyun Deng
Apr 20, 2019·Frontiers in Endocrinology·Hideyuki Oguro
Jun 2, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Rinad A AlgehaniAhmed M Al-Abd

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis